(Desogestrel and Ethinyl Estradiol Tablets)
RECLIPSEN™ Tablets provide an oral contraceptive regimen of 21 white round tablets each containing 0.15 mg desogestrel (13-ethyl-11-methylene-18, 19-dinor-17 alpha-pregn-4-en-20-yn-17-ol) and 0.03 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3, 17, diol).
RECLIPSEN™ Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Media Articles Related to Reclipsen (Desogestrel / Estradiol)
LARC versus SARC: Major study demonstrates clear benefits of long-acting reversible contraception compared to short-acting reversible contraception
Source: Sexual Health / STDs News From Medical News Today [2016.09.22]
Benefits of increased voluntary uptake of LARC may extend to wider populations than previously thought, according to a major study in the American Journal of Obstetrics and Gynecology.
Published Studies Related to Reclipsen (Desogestrel / Estradiol)
Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. [2011.01]
OBJECTIVE: To compare complications of third and second generation oral contraceptive pills (OCPs)... CONCLUSION: In comparison with the LNG+EE OCP, the DSG+EE OCP is a contraceptive pill that significantly decreases the severity of acne and hirsutism, without any significant change in weight.
Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. [2009.07]
BACKGROUND: The study was conducted to investigate whether hormonal contraceptives administered via the oral and vaginal route exert a similar effect on insulin sensitivity (SI)... CONCLUSIONS: The present data indicate that in contrast to OC use, vaginal contraception with the ring does not deteriorate SI. The vaginal ring may represent an appropriate choice for long-term contraception in women at risk for developing diabetes mellitus or metabolic syndrome.
Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. [2009.02]
BACKGROUND: Second-generation and third-generation oral contraceptives containing 30 mcg or more of ethinylestradiol (EE) decrease insulin sensitivity (SI). In this study, we investigated whether SI is decreased by contraceptives containing lower doses EE or by progestins with antiandrogenic properties... CONCLUSIONS: The present study confirms that DSG, even when associated with low EE dose, decreases SI. By contrast, EE/CMA does not deteriorate SI and induces a favorable lipid profile.
Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. [2007.12]
OBJECTIVE: To assess the effect of a new progestin progestogen only pill (desogestrel) versus an oral contraceptive in the treatment of recurrent endometriosis... CONCLUSIONS: Both desogestrel and an oral estro-progestinic were effective, safe and low cost therapy of pain symptoms after endoscopic surgery for endometriosis, the former showing an impact on breakthrough bleeding, the later an incidence on body weight increase.
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. [2006.04]
PURPOSE: In this open-label, randomized study, we assessed the effects on hemostasis of two combined oral contraceptives containing drospirenone (DRSP) as progestogen component... CONCLUSION: The changes in the hemostatic variables for DRSP/20EE were less pronounced compared to DSG/30EE and DRSP/30EE. The results were in accordance with previous reports on effects of similar OCs.
Clinical Trials Related to Reclipsen (Desogestrel / Estradiol)
NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles [Terminated]
Presently, a long protocol in an In Vitro Fertilization (IVF) cycle, patients need to take
Marvelon, a drug that inhibits the follicular development at the beginning of the cycle in
order to better control and also plan the onset of the ovary stimulation with gonadotropin.
Marvelon is taken daily as soon as menstruation starts for a period of 14 to 21 days.
Ideally, it has to be taken at the same time everyday and not be forgotten. This may cause
higher stress level for some users. Presently on the market, there is a ring-shaped
contraceptive device inserted in the vagina at day 1 of the cycle called NuvaRing. The
purpose of this device is similar to an oral contraceptive. However, the benefit of NuvaRing
is that it can be left in place for a period of up to 35 days without any other manipulation
and keep an adequate rate of hormone for contraception. Moreover, NuvaRing shows better
hormone stability in the blood. Although the side effects and the benefits are comparable
for the two treatments, some studies have shown that more patients would respect the
treatment with NuvaRing and that the level of satisfaction would be higher in women using
NuvaRing when contraception is needed.
The purpose of the study is to compare the rate of satisfaction as well as the level of
stress in women using Marvelon daily or NuvaRing with single insertion in a long protocol.
Moreover, this study allow us to verify if using NuvaRing, a vaginal contraceptive releasing
constant daily doses for up to 35 days will allow us to facilitate the planning of In Vitro
Fertilization cycles in long protocol.
Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083) [Completed]
The purpose of this study is to evaluate the efficacy and safety of Marvelon® in the
prevention of pregnancy.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
New Treatments for Troublesome Bleeding in Implanon Users [Not yet recruiting]
Most Implanon users experience a reduction in the frequency and volume of menstrual
bleeding, but a substantial minority experience unpredictable and frequent and/or prolonged
episodes of bleeding. This is a double blind, placebo controlled, randomised study with an
additional randomised non-blinded arm. Two hundred women between the ages of 18-45 years,
who are Implanon users with prolonged or frequent breakthrough bleeding (WHO definition)
will be recruited and randomised into 4 equal-sized treatment groups of 50 women assigned to
Marvelon 7 days or 21 days, NuvaRing 21 days or placebo. Recruited subjects will maintain a
daily menstrual diary chart for a minimum of 90 days prior to randomisation, and will be
enrolled into the treatment phase provided that they have met one of the World Health
Organization criteria for prolonged or frequent bleeding Following the initial 90 day
record, eligible women will begin designated treatment on day 1 of the next episode of
bleeding or spotting. Analysis of the subsequent menstrual pattern will begin from day 1 of
that bleeding/spotting episode and will continue through 90 days.
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception [Completed]
The purpose of this study is to evaluate the effectiveness in terms of prevention of
pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in
healthy Chinese women
Hormonal Contraception and Vaginal Health [Completed]
The purpose of this study is to help determine if the route by which women receive hormonal
contraception causes different changes to occur in the lining of the vagina. The
investigators plan to compare an oral route (taking birth control pills) with a vaginal
route (using a vaginal ring).
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Reclipsen has an overall score of 10. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Reclipsen review by 31 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || skin breakouts/birth control|
|Dosage & duration:|| || 0.15 mg, .03 mg taken one pill per day for the period of one year|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Treatment benefits include clear, glowing skin, regular menstrual cycles, and reliable birth control.|
|Side effects:|| || Treatment side effects include breast tenderness for about a month after first doseage, and some ovular soreness.|
|Comments:|| || Treatment details include taking a pill eachday at the same time for maximum effectiveness in preventing pregnancy, and taking the 5 placebo pills to help remember to take a pill every day.|
Page last updated: 2016-09-22